Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyrroloquinoline quinone-dependent dehydrogenases (PQQ-DHs) are a specialized class of oxidoreductases, also known as quinoproteins, that utilize the redox-active cofactor pyrroloquinoline quinone (PQQ) to catalyze the oxidation of various substrates including alcohols, sugars, and amines (Matsushita et al., 2002). These enzymes are primarily located in the periplasmic space of Gram-negative bacteria, where they facilitate the initial steps of substrate oxidation and channel electrons directly into the respiratory chain, often bypassing the need for NAD(P)+ (Klinman & Bonnot, 2014). A prominent member of this family is PQQ-dependent glucose dehydrogenase (GDH-PQQ), which has been extensively utilized in the development of blood glucose monitoring systems due to its high catalytic efficiency and lack of oxygen interference (FDA, 2009). While PQQ-dependent enzymes are not natively expressed in humans, PQQ itself is found in human tissues and breast milk, leading to its investigation as a potential bioactive compound with neuroprotective and antioxidant properties (UniProt). From a therapeutic perspective, these enzymes represent potential targets for the development of novel antibacterial agents designed to disrupt bacterial energy metabolism. However, a significant clinical challenge associated with GDH-PQQ-based diagnostics is the lack of substrate specificity, which historically led to life-threatening errors in glucose readings for patients receiving treatments containing maltose or icodextrin (FDA, 2009).
These enzymes catalyze the oxidation of substrates (such as glucose or alcohols) by transferring two electrons and two protons to the PQQ prosthetic group to form PQQH2; the reduced cofactor is then re-oxidized by transferring electrons to an external acceptor, typically a cytochrome or ubiquinone, within the bacterial electron transport chain (Matsushita et al., 2002).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyrroloquinoline quinone-dependent dehydrogenase (PQQ-DH) (PQQ-DH).